Venture capitalists have largely ignored Type 1 diabetes, backing just 7 related U.S. startups since the beginning of 2015. Instead they've focused their diabetes dollars on Type 2, a metabolic disease whose cause is largely understood, whereas Type 1 is a more complicated autoimmune condition with fewer patients. Now, Bain Capital intends on backing dozens of companies through a venture philanthropy fund.